SINCE the introduction of histological grading in breast cancer by von Hausemann (1892) its contribution to knowledge of the disease and its appropriate role in the choice of treatment has been a matter of dispute. A primary difficulty with most grading methods has been the lack of reproducibility in the assessment of grade, both by different pathologists and by the same pathologist on different occasions (Foote, 1959) . Not unreasonably these difficulties have led to some resistance to the wide adoption of one of these methods for the purpose of guidance in the management of treatment.
Nevertheless Bloom (1950; 1-962) and Bloom & Richardson (1957) showed how successful grading by one pathologist could be in predicting survival. Schi0dt (1966) reviewed many of the different grading methods proposed, and found Bloom & Richardson's (1957) method conveniently simple to apply. Both Schiodt and Bloom found the reproducibility of grade on repeated assessments by the same pathologist to be acceptably high. This method of grading has since been adopted by WHO (Scarff & Torloni, 1968) . Schi0dt (1966) and Bunting et al. (1976) have both confirmed the close relationship of grade to length of survival following treatment. Hartveit (1971) has discussed another grading method for which she claims a greater predictive power than Bloom's method, but her results are as yet unconfirmed.
Since 1958 one of us (E.M.McC.) has been grading breast carcinomas according to Bloom and Richardson's method, using histological material submitted to the Mersey Regional Cancer Registry by pathologists in the Liverpool region, North WVales and the Isle of Man. This paper examines the survival of patients treated by radical surgery in relation to the histological grade and other prognostic factors. Recently statistical methodology has been developed to allow simultaneous assessment of several prognostic factors in survival. One such method (Brown, 1975) has been used in this investigation.
Data
The study is based on the records of the Mersey Regional Cancer Registry (MRCR) for the years 1961-68, which registers from a population of an area comprising the Liverpool Regional Hospital Board, the 5 old counties of North Wales (Anglesey, Caernarvonshire, Denbighshire, Flintshire, and Merionethshire) and the Isle of Man. During this period a total of 7493 cases of carcinoma of the breast were registered, but this study is limited to 3085 (1) Tubule formation (2) Hyperchromatism and mitosis (3) Irregularity of size, shape and staining of nuclei. Well-marked tubule formation is characteristic of a high degree of differentiation and indicates a favourable prognosis, and 1 point is awarded if the section shows well-marked tubule formation, 2 points if tubule formation is moderate and 3 points if there is little or no differentiation.
The greater the number of hyperchromatic or mitotic nuclei the worse the prognosis. One point is awarded if only an occasional hyperchromatic nucleus or mitotic figure is seen per high-power field, 2 points if there are 2-3 such figures in most fields and 3 points if the number is higher. One point is awarded if the nuclei are uniform in size, shape and staining, 2 points if there is moderate variation and 3 points if pleomorphism is marked.
The points allocated for each of the 3 criteria are added together; a total of 3-5 is graded I, 6-7 points graded II, and 8-9 points is graded III.
In most cases one section was sufficient for grading, but with larger growths it was sometimes necessary to examine several sections. When there was a definite variation in grade within a tumour then the grading of the most malignant area was allotted. (Fig. 1, 2 and 3 ). An analysis of the early years of grading showed considerable variation of the proportions of the grades, but for the years of analysis these were more stable (Table II) . Disease status at death (presence or absence of malignant disease) is thought to be a reasonably accurate record, being based on clinical assessment summarized in the annual follow-up information on the patient. It should be more (1975) seems appropriate for our data and a description is given in Appendix I. The analyses of the data using this model are performed by a programming package known as GLIM, that is available on the Liverpool University computer. The input for the programme consists of extracts from the 108 cross-tabulations mentioned earlier in this section. Each analysis (all causes of death and deaths from malignant disease) was performed on all 3085 records and repeated for the subset of 1759 records for which a histological grade had been allocated. The results of the analysis of deaths from all causes are described in some detail in this paper, and the results of death from malignant disease are described briefly in Appendix 2. Table III shows the distribution of each prognostic factor among the 3085 patients, and also among the subgroup of 1759 patients allocated a tumour grade. Two points that might be stressed are that the size of tumour was recorded in only 30% of the records and that the distribution of the 1759 patients over histopathological grades I, II, and III was in the approximate 3:5:6 ratio. The results of the analysis using the mathematical model (Brown, 1975) are presented in detail in Appendix 2. These results indicate that, of the 4 prognostic factors considered, only histological grade and clinical stage are in fact of importance; moreover in this series histological grade is found to be more important than Bloom, Bunting and Schi0dt all comment on the different time-patterns of deaths according to tumour grade. This is confirmed in our study. For Grade III tumours, the peak rise of death is between the first and second year after treatment, and for Grades I and II tumours the risk of death reaches its peak between 4-6 years after treatment. However, further analysis (not described here) suggests that the position of peaks in these latter two groups may depend on the clinical stage, but a larger number of patients and a longer follow-up would be required to clarify this point.
RESULTS
The importance of Bloom's histological grade as a prognostic factor, as now -0--4boo-demonstrated in 4 independent reports involving large numbers of breast-cancer patients, raises issues on the design, analysis and interpretation of clinical trials in the primary management of this disease.
By including histological grade as a covariate in the statistical comparison of two treatments (Armitage & Gehan, 1974) we would make such a comparison more precise. For example, it can be shown that if Bloom's results (1962) hold true in a trial of treatment for Clinical Stage 2 disease, including histological grade in the analysis would be equivalent to having 13% more patients in the trial (see Appendix 3). Thus, by arranging for the tumours to be graded by a pathologist, it should be possible to obtain an answer from the trial at an earlier date. In addition such a trial could tell us whether the difference in response to each treatment was the same for high-grade and lowgrade tumours. For example, cytotoxic therapy adjuvant to surgery may be more effective than surgery alone for highgrade tumours but not for low-grade tumours. Fisher & Fisher (1977) have recently made a similar recommendation that histological information be used in breast cancer trials.
It should be noted that if histological grade is used in the analysis of breast-cancer studies based on survival data, comparing the survival according to grade by the logrank test (Peto et al., 1977) is not particularly appropriate, since the "risks of death" (or hazards) for the different grades do not bear constant ratio to each other over time. This point is illustrated in Fig. 7 . In such a case timedependent variables should be introduced, and among others Brown's (1975) method used in this study might be considered. However, it may still be appropriate to compare the treatment groups themselves by the logrank test after the appropriate stratification (Peto et al., 1977) .
The data presented here also have implications for the results of trials in breast cancer which have been reported after follow-up times of at most 3 years (Fisher et al., 1975; Bonadonna et al., 1976; Multicentre Breast Cancer Chemotherapy Group, 1977) . Differences between treatments found in these studies may reflect only the response of Grade III tumours (Fig. 7) . It may be too early to say whether tumours of low grades respond in the same way.
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APPENDIX I. APPLICATION OF BROWN S MODEL
We illustrate the method using the simple case where the relationship between survival and a single prognostic factor is to be assessed. We suppose that the prognostic factor has 2 possible values. The time after the first treatment is divided into a number of periods. In this study 6 periods were chosen: 0-1 year, 1-2 years, 2-4, 4-6, 6-8 and 8-10 years.
To describe Brown's model it is necessary to introduce the idea of a "hazard". The hazard for a particular period is defined as the probability that a patient who has survived to the beginning of the period will die at some time during that period. Thus for a period of one year the hazard is identical to the "risk of death" which was introduced in the Results section of the main text, while for a period of 2 years the hazard is twice the risk of death.
Let the hazard for a patient who has value i of the prognostic factor (where i=1, or 2) and is at risk during Period t (where t= 1, 2, 3, 4, 5, or 6) be denoted by Pit. Brown's model postulates that logitPit-log( Pit) =M+T'i+Tt+ (VT)it (i 1, 2; t=1, 2, 3, 4, 5, 6) (Al) where M is the overall effect, Vi is an effect due to the ith value of the prognostic factor, Tt is an effect due to the tth time periocl and (VT)it is an effect due to the "interaction" between the prognostic factor and the periods.
The values of M, Vi, Tt and (7T)it can be so chosen that the data used in this study are fitted exactly by the model. However, if certain of the terms on the right-hand side of expression (Al) are constrained to be equal to zero, the data will not necessarily be fitted exactly. The goodness-of-fit of such a constrained model is measured by the value of twice the maximized log-likelihood; whenever this value is significantly large, the corresponding model is rejected as an inadequtate description of the data. In our example the constrained mnodels of interest are:
The time-effect Tt is regarded as a basic component of the model, and the prognostic factor effect V1 is therefore never included in the model without Tt. The analysis proceeds by searching through these models to find the simplest (i.e. the model with the least terms) which is judged an adequate description of the data. If for example model (A2c) is judged to be an adequate description, it follows that the interaction terms (VT)it are not really required.
Another way of viewing the results is to consider how much improvement is achieved in the goodness-of-fit by adding extra terms into the model. For example, if the goodness-of-fit criterion for Model A2c is not much smnaller than that for Model A2b, it would follow that the terms Vi add little to the description of the data, once the terms 1M1 and Tt lhave been included. Thuts one may measure the importance of prognostic factors by the lifferences in the goodness-of-fit criteria of the 2 appropriately chosen models.
The method can be used in a similar way to examine simultaneously the importance of several prognostic factors.
The analysis was carried out using the GLIM programme package (Nclder, 1974) Table A2 is therefore the more reliable (but see the Discussion section in the main text for further comments). The prognostic factor tumour size was not found to be of any importance, once grade and stage were included in the model. Age, however, was of importance, both as a main effect and also through an age-grade interaction. It was found that on further analysis, when deaths from malignant disease only were considered, the contribution of age became negligible, although time, stage, grade and the timegrade interaction remained important.
We concluded therefore that the age effect was due to deaths from nonmalignant disease in old age. In the interests of brevity the results of these analyses are not included. (A) and N receive the alternative treatment (B). Suppose also that in the total group of 2N patients, the number with histological grades I, II and III are 0-5N, N and 0-5N respectively. Finally, suppose that experience shows that the 5-year survival rate for patients with Grades I, II and III following conventional therapy (A) are 71%, 43% and 24% respectively. These figures are taken from Bloom (1962) .
We will consider a comparison of Treatments A and B based on 5-year survival rates. Normally one would use the survival times themselves in any treatment comparison (Peto et al., 1977) . However, we use here the cruder method of comrparing the 5-year rates for the sake of simplicity.
Assume firstly that no knowledge of histological grade has been obtained for this trial. Then the expected 5-year survival rate in the treatment Group A is: (0.25 x 71%)+(0O5 x 43%)+(025 x 24%)
=45.25%
Under the null hypothesis (that there is no difference between treatments) the standard error of the difference in pro- VN\V\iN' e where N'= 113 N Thus we have the equivalent of 13 % more patients in the trial.
